I do not tend to offer neoadjuvant endocrine therapy to premenopausal women, unless it is in a clinical trial setting. There is limited data available but 6 months of ovarian suppression plus an aromatase inhibitor was found to be more effective in reducing tumor size than tamoxifen (clinical parti...